Sign in
CNSP Stock Price, Chart, Stats & News
CNS Pharmaceuticals, Inc.
Save
CNS Pharmaceuticals, Inc. (CNSP) does not currently pay a dividend.
7.75M
Market cap
–
Current P/E
–
Forward P/E
CNSP chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -110.13% |
ROE | -130.12% |
D/E | 0.00x |
Interest coverage ratio | -863.74x |
CNSP valuation
P/E | – |
P/S | – |
P/B | 0.14x |
P/CF | -0.08x |
P/FCF | -0.09x |
P/OCF | -0.08x |
PEG | -0.00x |
EV multiple | -0.86x |
About
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements.
Similar securities
Based on sector and market capitalization
Report issue